Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes by McKay, James D. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Large-scale association analysis identifies new lung cancer susceptibility loci and
heterogeneity in genetic susceptibility across histological subtypes
McKay, James D.; Hung, Rayjean J.; Han, Younghun; Zong, Xuchen; Carreras-Torres,
Robert; Christiani, David C.; Caporaso, Neil E.; Johansson, Mattias; Xiao, Xiangjun; Li,
Yafang; Byun, Jinyoung; Dunning, Alison; Pooley, Karen A.; Qian, David C.; Ji, Xuemei; Liu,
Geoffrey; Timofeeva, Maria N.; Bojesen, Stig E.; Wu, Xifeng; Marchand, Loic Le; Albanes,
Demetrios; Bickeböller, Heike; Aldrich, Melinda C.; Bush, William S.; Tardon, Adonina;
Rennert, Gad; Teare, M. Dawn; Field, John K.; Kiemeney, Lambertus A.; Lazarus, Philip;
Haugen, Aage; Lam, Stephen; Schabath, Matthew B.; Andrew, Angeline S.; Shen, Hongbing;
Hong, Yun Chul; Yuan, Jian Min; Bertazzi, Pier Alberto; Pesatori, Angela C.; Ye, Yuanqing;
Diao, Nancy; Su, Li; Zhang, Ruyang; Brhane, Yonathan; Leighl, Natasha; Johansen, Jakob
S.; Mellemgaard, Anders; Saliba, Walid; Haiman, Christopher A.; Wilkens, Lynne R.;
SpiroMeta Consortium; Rafnar, Thorunn; Thorgeirsson, Thorgeir E; Reginsson, Gunnar W.;
Brennan, Paul; Landi, Maria Teresa; Amos, Christopher I
Published in:
Nature Genetics
DOI:
10.1038/ng.3892
Publication date:
2017
Document version
Peer reviewed version
Citation for published version (APA):
McKay, J. D., Hung, R. J., Han, Y., Zong, X., Carreras-Torres, R., Christiani, D. C., ... Amos, C. I. (2017). Large-
scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility
across histological subtypes. Nature Genetics, 49(7), 1126-1132. https://doi.org/10.1038/ng.3892
Download date: 03. Feb. 2020
Large-scale association analysis identifies new lung cancer 
susceptibility loci and heterogeneity in genetic susceptibility 
across histological subtypes
A full list of authors and affiliations appears at the end of the article.
Summary
While several lung cancer susceptibility loci have been identified, much of lung cancer heritability 
remains unexplained. Here, 14,803 cases and 12,262 controls of European descent were genotyped 
on the OncoArray and combined with existing data for an aggregated GWAS analysis of lung 
cancer on 29,266 patients and 56,450 controls. We identified 18 susceptibility loci achieving 
genome wide significance, including 10 novel loci. The novel loci highlighted the striking 
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heterogeneity in genetic susceptibility across lung cancer histological subtypes, with four loci 
associated with lung cancer overall and six with lung adenocarcinoma. Gene expression 
quantitative trait analysis (eQTL) in 1,425 normal lung tissues highlighted RNASET2, 
SECISBP2L and NRG1 as candidate genes. Other loci include genes such as a cholinergic 
nicotinic receptor, CHRNA2, and the telomere-related genes, OFBC1 and RTEL1. Further 
exploration of the target genes will continue to provide new insights into the etiology of lung 
cancer.
Lung cancer continues to be the leading cause of cancer mortality worldwide1. Although 
tobacco smoking is the main risk factor, the heritability of lung cancer has been estimated at 
18%2. Genome-wide association studies (GWAS) have previously identified several lung 
cancer susceptibility loci including CHRNA3/5, TERT, HLA, BRCA2, CHEK23,4, but most 
of its heritability remains unexplained. With the goal of conducting a comprehensive 
characterization of common lung cancer genetic susceptibility loci, we undertook additional 
genotyping of lung cancer cases and controls using the OncoArray5 genotyping platform, 
which queried 517,482 SNPs chosen for fine mapping of susceptibility to common cancers 
as well as for de novo discovery (Supplementary Table 1, and Online Methods). All 
participants gave an informed consent, and each study obtained local ethics committee 
approval. After quality control filters (Online Methods), a total of 14,803 cases and 12,262 
controls of European ancestry were retained and underwent imputation techniques to infer 
additional genotypes for genetic variants included in the 1000 Genomes Project data (Online 
Methods). Logistic regression was then used to assess the association between variants 
(n=10,439,017 SNPs) and lung cancer risk, as well as by predominant histological types and 
by smoking behavior (Online Methods). Fixed-effects models (Online Methods) were used 
to combine the OncoArray results with previously published lung cancer GWAS3,4,6, 
allowing for analysis of 29,266 patients and 56,450 controls of European descent (Table 1). 
There were no signs of genomic inflation overall or for any subtypes (Supplementary Figure 
1) indicating little evidence for confounding by cryptic population structure (Online 
Methods). All findings with a P-value less than 1×10−5 are reported in Supplementary Table 
2. As shown in Figure 1, the genetic architecture of lung cancer varies markedly among 
histological subtypes, with striking differences between lung adenocarcinoma and squamous 
cell carcinoma. Manhattan plots for small cell carcinoma (SCLC), ever and never smoking 
are displayed in Supplementary Figure 2. The array heritability estimates were comparable 
among histological subsets, but squamous cell carcinoma appeared to share more genetic 
architecture with small cell carcinoma (SCLC) than with adenocarcinoma (Supplementary 
Table 3).
Table 2 presents summary results of all loci with sentinel variants (defined as the variant 
with the lowest P-value at each locus) that reached genome-wide significance (P-value < 
5×10−8) for lung cancer overall and by histological subtypes. Sentinel variants stratified by 
new and previous genotyping and additional statistical significance assessed based on the 
number of effective tests, Approximate Bayes Factors, and Bayesian False Discovery 
Probability are presented in Supplementary Tables 4 and 5, respectively. Repeat genotyping 
of 12% of the OncoArray genotyped samples confirmed the fidelity of the genotyping or 
imputation for the risk loci, and showed excellent concordance of imputation for SNPs with 
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MAF>0.05 (Online Methods, Supplementary note). Among the 18 loci that reached GWAS 
significance, 10 had not reached significance in a genome-wide scan (Figure 1). Of these, 
four novel loci were associated with lung cancer overall, and six with adenocarcinoma.
To decipher the association between these 18 loci and lung cancer risk, we further 
investigated their association with gene expression level in normal lung tissues (n=1,425) 
(Supplementary Table 6, Supplementary Figure 3), genomic annotations (Supplementary 
Table 7), smoking propensity (cigarettes smoked per day (n=91,046) and Fagerström Test 
for Nicotine Dependence metrics (n=17,074)) (Table 2). Previous studies have shown shared 
risk for lung cancer and COPD through inflammation and ROS pathways7; therefore, we 
also assessed the association between sentinel SNPs and reduced lung capacity through 
spirometry measurements (forced expiratory volume in 1 second [FEV1], forced vital 
capacity [FVC], n =30,199) (Table 2 and Online Methods).
Variants at 4 novel loci (1p31.1, 6q27, 8p21, 15q21.1) were associated with lung cancer risk 
overall, with little evidence for heterogeneity among subtypes (Supplementary Figure 4). 
The 1p31.1 locus, recently identified in a pathway-based analysis of the TRICL data8, 
represented by rs71658797 (Odds Ratio [OR]=1.14, 95% Confidence Interval [CI] 1.09–
1.18, P-value=3.25 × 10−11), is located near FUBP1/DNAJB4 (Supplementary Figure 4). At 
6q27, rs6920364 was associated with lung cancer risk with an OR of 1.07 (95% CI 1.04–
1.09, P-value=2.9×10−8) with little heterogeneity found by smoking status (Supplementary 
Figure 4). This locus is predicted to regulate RNASET2 (Supplementary Figure 5, 
Supplementary Table 7). We identified rs6920364 as a lung cis-eQTL for RNASET2, an 
extracellular ribonuclease, in all five cohorts tested (Supplementary Table 6), with increased 
lung cancer risk correlating with increased RNASET2 expression (Figure 2). Variants 
correlated with rs6920364 (r2>0.88) have been noted in GWAS of Crohn’s disease and 
inflammatory bowel disease9–13.
The 8p21 locus has been suggested as a lung cancer susceptibility locus by pathway 
analysis14 and now confirmed at GWAS significance level. It is a complex locus represented 
by sentinel variant rs11780471 associated with lung cancer (OR=0.87, 95% CI 0.83–0.91, P-
value=1.69×10−8) (Supplementary Figure 4), but this region contained additional 
uncorrelated variants (pairwise r2< 0.10) associated with lung cancer (Supplementary Table 
8). Multivariate analysis was consistent with multiple susceptibility alleles at this locus 
(Supplementary Table 8). In contrast to lung tissue (Figure 3A, Supplementary Table 6, 
Supplementary Figure 3), we noted that the alleles associated with lung cancer tended to be 
associated with cerebellum expression of CHRNA2, a member of the cholinergic nicotinic 
receptor (Figure 3B). The CHRNA2 rs11780471 cis-eQTL effect in the brain was limited to 
the cerebellum (Figure 3C), a region not traditionally linked with addictive behavior, but 
where an emerging role is suggested15. We therefore investigated rs11780471 in the context 
of smoking behavior (Supplementary Methods). Unlike the well-described 15q25.1 
(rs55781567) CHRNA5 locus (Table 2), rs11780471 was not associated with number of 
cigarettes smoked per day or the FTND metrics (Figure 3D). Nevertheless, lung cancer risk 
allele carriers of rs11780471 tended to be smokers and initiated smoking at earlier ages 
(Figure 3D), implying that this variant’s association with lung cancer could potentially be 
mediated via influencing aspects of smoking behavior. Another potentially relevant gene in 
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this region is EPHX2, a xenobiotic metabolism gene. Although the sentinel variant is not an 
eQTL for EPHX2 in lung tissues, other associated variants in the region are (e.g. 
rs146729428, p-value of 1.77×10−7 (Supplementary Table 2) and 5 × 10−4 for lung cancer 
risk and eQTL, respectively). A potential synergistic role of both EPHX2 and CHRNA2 on 
lung cancer etiology cannot be excluded.
The genetic locus at 15q21 (rs66759488) was shown to be associated with lung cancer 
(OR=1.07, 95% CI 1.04–1.10, p=2.83×10−8) overall and across lung cancer histologies 
(Supplementary Figure 4). Genomic annotation suggests that genetic variants correlated with 
rs66759488 may influence the SEMA6D gene (Supplementary Table 7), but there was no 
clear eQTL effect (Supplementary Table 6), and this variant did not appear to have a major 
influence on smoking propensity or lung function (Table 2).
For specific lung cancer histology subtypes, we identified 6 novel loci associated with lung 
adenocarcinoma (15q21, 8p12, 10q24, 20q13.33, 11q23.3 and 9p21.3) (Table 2). The locus 
at 15q21 (rs77468143, OR=0.86, 95% CI 0.82–0.89, p=1.15×10−16) is predicted to target 
SECISBP2L (Supplementary Figure 5), and expression analysis indicated rs77468143 to be 
a cis-eQTL for SECISBP2L in lung tissue in all eQTL cohorts tested (Supplementary Table 
6). The genetic risk allele appears to correlate with decreased expression levels of 
SECISBP2L (Figure 2, Supplementary Figure 5), an observation that is consistent with 
SECISBP2L being down regulated in lung cancers16. rs77468143 was nominally associated 
with lung function (Table 2), potentially implicating inflammation of lung as part of the 
mechanism at this locus.
At 8p12, expression analysis indicated that the alleles associated with lung adenocarcinoma 
(represented by the sentinel variant rs4236709 (Table 2)), also appear to be a lung cis-eQTL 
for the NRG1 gene (Supplementary Table 6, Supplementary Figure 5). This region also 
contains putative regulatory regions (Supplementary Figure 5). Somatic translocations of 
NRG1 are infrequently observed in lung adenocarcinomas17. While somatic translocations at 
8p12 generally take place in never smokers and are linked with ectopic activation of NRG1, 
rs4236709 was associated with lung cancer in both ever and never smokers (Supplementary 
Figure 4) and its genetic risk correlated with decreased NRG1 expression (Figure 2). 
Interestingly, 6q22.1 variants located near ROS1, another gene somatically translocated in 
lung adenocarcinoma and for which nearby germline variants were associated with never 
smoking lung adenocarcinoma in Asian women18, were associated with lung 
adenocarcinoma at borderline genome wide significance (rs9387479; OR=0.92, 95% CI 
0.89–0.95, p=6.57×10−8) (Supplementary Table 2).
Three of the sentinel variants associated with lung adenocarcinoma are located near genes 
related to telomere regulation; rs7902587 (10q24) and rs41309931 (20q13.33) near OBFC1 
and RTEL1, respectively, and rs2853677 near TERT as previously noted19,20. The variants at 
10q24 associated with lung adenocarcinoma also appear to be associated with telomere 
length (Supplementary Figure 6). By contrast, and consistent with observations with 
20q13.33 variants associated with glioma21, the variants associated with telomere length at 
20q13.33 were not necessarily those associated with lung adenocarcinoma (Supplementary 
Figure 6). Nevertheless, more generally the variants associated by GWAS with longer 
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telomere length22 appear linked with risk of lung adenocarcinoma23 and glioma21,24, a 
finding consistent with our expanded analysis here (Supplementary Figure 6).
We additionally identified a complex locus at 11q23.3. The sentinel variant rs1056562 
(OR=1.11, 95% CI 1.07–1.14, p=2.7×10−10) is more prominently associated with lung 
adenocarcinoma (Supplementary Figure 4). rs1056562 was correlated with expression of 
two genes at this locus, AMICA1 and MPZL3 (Supplementary Table 6). However, there did 
not appear to be a consistent relationship between the alleles related with AMICA1 and 
MPZL3 gene expression and those with lung adenocarcinoma (Figure 2, Supplementary 
Table 9), suggesting that expression of these genes alone is unlikely to mediate this 
association.
At 9p21.3 we identified rs885518 that appeared to be associated with lung adenocarcinoma 
(OR=1.17, 95% CI 1.11–1.23, p=6.8×10−10). 9p21.3 is a region containing CDNK2A and 
variants associated with multiple cancer types, including lung cancer. Nevertheless, 
rs885518 is located approximately 200kb centromeric the previously described variants 
(Supplementary Figure 4) and shows little evidence for LD (all pairwise r2< 0.01) with 
rs1333040, a variant previously associated with lung squamous cell carcinoma3 and 
rs62560775, another variant suggested to be associated with lung adenocarcinoma25 that we 
confirm to genome significance here. Intriguingly, these variants appear to confer 
predominant associations with different lung cancer histologies suggesting that they are 
independent associations (Supplementary Figure 7).
Aside from the clear smoking-related effects on lung cancer risk through the CHRNA5 and 
CYP2A6 regions and association with CHRNA2 noted above, the rest of variants we have 
identified do not appear to clearly influence smoking behaviors (Table 2), implying that 
these associations are likely mediated by other mechanisms. Nevertheless, there is shared 
genetic architecture between smoking behavior and lung cancer risk, consistent with the 
notion that genetic variants do influence lung cancer risk also through behavioral 
mechanisms (Supplementary Figure 8).
In conclusion, the genetic susceptibility alleles we describe here explain approximately 
12.3% of the familial relative risk previously reported in family cancer databases26,27, out of 
which 3.5% was accounted for by the novel loci. Our findings emphasize striking 
heterogeneity across histological subtypes of lung cancer. We expect that further exploration 
of the related target genes of these susceptibility loci, as well as validation and identification 
of new loci, will continue to provide insights into the etiology of lung cancer.
Online methods
This work is conducted based on the collaboration of Transdisciplinary Research of Cancer 
in Lung of the International Lung Cancer Consortium (TRICL-ILCCO) and the Lung 
Cancer Cohort Consortium (LC3). The participating studies are individually described in the 
Supplementary Note.
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OncoArray genotyping
Genotyping was completed at the Center for Inherited Disease Research (CIDR), the Beijing 
Genome Institute, the HelmholtzCenter Munich (HMGU), Copenhagen University Hospital, 
and the University of Cambridge. Quality control steps follow the approach described 
previously for the OncoArray5 (Supplementary Note).
Genotype quality control
After removing the 1,193 expected duplicates, QC procedures for the 43,398 individuals are 
summarized in Supplementary Note Figure 1. Standard quality control procedures (detailed 
in the Supplementary Note) were used to exclude underperforming individuals (number of 
DNAs=1,708) and genotyping assays (judged by success rate, genotype distributions 
deviated from that expected by Hardy Weinberg equilibrium, number of variants=16,149). 
After filtering, there were 517,482 SNPs available for analysis.
Identity by Descent (IBD) was calculated between each pair of samples in the data using 
PLINK to detect unexpected duplicates and relatedness. Details are described in 
Supplementary Note. 340 unexpected duplicated samples (proportion IBD>0.95) and 940 
individuals were removed as related samples with proportion IBD between 0.45 and 0.95. Of 
these, 721 of them were expected first degree relatives. In total, 0.56% of the total samples 
were removed as unexpected duplicates or relatives in the QC analysis. We additionally 
considered the potential that more distant familial relationships could have impacted the 
results. However, further restriction to proportion IBD > 0.2 identified 139 second degree 
relatives and excluding these had minimal impact on the association results (Supplementary 
Note Table 1).
Complete genotype data for X chromosomes were used to verify reported sex by using 
PLINK sex inference and a support vector machine procedure resulting in 306 non-
concordant samples being removed (Supplementary Note).
We used the program FastPop (http://sourceforge.net/projects/fastpop/)28 was used to 
identify 5,406 individuals of non-European ancestry (Supplementary Note) resulting in a 
final association analysis including 14,803 lung cancer cases and 12,262 controls.
We confirmed the fidelity genotyping (directly and imputed) of the OncoArray platform by 
considering concordance of these genotypes relative to genotypes obtained from analogous 
genotyping platform (Supplementary Note).
Imputation analysis
A detailed description of the imputation procedures used by the OncoArray consortium and 
in this Lung Oncoarray project, has been described previously.5 Briefly, the reference 
Dataset was the 1000 Genomes Project (GP) Phase 3 (Haplotype release date October 2014). 
The forward alignment of SNPs genotyped on the Oncoarray was confirmed by blasting the 
sequences used for defining SNPs against the 1000 Genomes. Any ambiguous SNPs were 
subjected to a frequency comparison to 1000 Genomes variants. Allele frequencies were 
calculated from a large collection of control samples from Europeans (from 108,000 
samples) and Asians (11,000 samples). A difference statistic is calculated by the formula: (|
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p1-p2|- 0.01)2/((p1+p2)(2-p1-p2)) where p1 and p2 are the frequencies our dataset and in the 
1000 genomes respectively5. A cutoff of 0.008 in Europeans and 0.012 in Asians is needed 
to pass. SNPs where the frequency would match if the alleles were flipped were excluded 
from imputation, but not from the association analyses.5 AT/GC SNPs were not present in 
previously genotyped lower density arrays. Because all imputation was performed to the 
same standard all SNPs had the same orientation at the time of imputation. The OncoArray 
whole genome data were imputed in a two-stage procedure using SHAPEIT to derive phased 
genotypes, and IMPUTEv229 to perform imputation of the phased data. We included for 
imputation only the more common variant if more than one variant yielded a match at the 
same position. The detailed parameter settings are in the Supplementary Note.
Meta-analysis of lung cancer GWAS
FlashPCA30 was run for principal component analysis (PCA) to infer genetic ancestry by 
genotype. The regression model assumed an additive genetic model and included the first 
three eigenvalues from FlashPCA as covariates. For imputed data of smaller sample size, 
which was enrolled in our analysis later, we changed the method score to EM algorithm to 
accommodate smaller sample size.
We combined imputed genotypes from 14,803 cases and 12,262 controls from the 
OncoArray series with 14,436 cases and 44,188 controls samples undertaken by the previous 
lung cancer GWAS3,4,6, including studies of IARC, MDACC, SLRI, ICR, Harvard, NCI, 
Germany and deCODE as described previously3,4,6, and we ensured that there were no 
overlap between the ATBC, EAGLE and CARET studies included in both the previous 
GWAS and current OncoArray dataset by comparing the identity tags (IDs) of all study 
participants.
In addition to lung cancer, analyses by histological strata (adenocarcinoma, squamous cell 
carcinoma, small cell carcinoma (SCLC) and smoking status (Ever/Never) was assessed 
where data were available. Results from analyses defined by Ever and Never smoking strata 
did not identify any novel variants.
We conducted the fixed effects meta-analysis with the inverse variance weighting and 
random effects meta-analysis from the DerSimonian-Laird method31. All meta-analysis and 
calculations were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). As 
the same referent panel was used for all studies, all SNPs showed the same forward 
alignment profiles. We excluded poorly imputed SNPs defined by imputation quality R2 < 
0.3 or Info < 0.4 for each meta-analysis component and SNPs with a Minor allele frequency 
(MAF) >0.01 (except for CHEK2 rs17879961 and BRCA2 rs11571833 which we have 
validated extensively previously4. We generated the index of heterogeneity(I2) and P-value 
of Cochran’s Q statistic to assess heterogeneity in meta-analyses and considered only 
variants with little evidence for heterogeneity in effect between the studies (P-value of 
Cochran’s Q statistic >0.05). SNPs were retained for study provided the average imputation 
R-square was at least 0.4. For SNPs in the 0.4–0.8 range that reached genome wide 
significance results were evaluated for consistency with neighboring SNPs to assure a 
reliable inference. Due to the smaller sample size and fewer sites contributing in the strata of 
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Never Smokers and SCLC, we additionally required variants to be present in each of the 
meta-analysis components to be retained for these 2 stratified analyses.
Conditional analysis was undertaken using SNPTEST where individual level data was 
available and GCTA32 packages for the previous lung cancer GWAS, with the LD estimates 
obtained from individuals of European origin for the later. Results were combined using 
fixed effects inverse variance weighted meta-analysis as described above33.
Assessing Statistical Significance
Genome wide statistical significance was considered at P-values of 5 × 10−8 or lower, but we 
also presented significance per alternative criteria following Bonferroni correction for the 
number of effective tests or Bayesian False Discovery Probability (BFDP) described below.
To evaluate the effective number of tests we used the Li and Ji (2005)33 method which 
performs an initial step of filtering out SNPs with MAF<0.01 (imputation is less reliable for 
these and power is also limited for most odds ratios). Among the 4,751,148 markers with 
that MAF there were 1,182,363 effective tests.
The BFDP combines significance level, study power, and cost of false discovery and non-
discovery into consideration. The detailed procedures of this method are described in 
Wakefield, 200734. Essentially, the approximate Bayes Factor (ABF) which BFDP uses 
reflects how much the prior odds change in the light of the observed data (i.e. relative 
probability of the observed estimates under the null versus alternative hypothesis). Given the 
nature of GWA studies, we applied a flat prior for all variants at prior probability of 10−6 and 
10−8 to demonstrate the range of BFDP.
Annotation of susceptibility loci
We combined multiple sources of in silico functional annotation from public databases to 
help identify potential functional SNPs and target genes, based on previous observations that 
cancer susceptibility alleles are enriched in cis-regulatory elements and alter transcriptional 
activity. The details are described in the Supplementary Note.
eQTL analysis of lung cancer sentinel variants
To investigate the association between the sentinel variants and mRNA expression, we used 
three different eQTL datasets: (i) Microarray eQTL study: The lung tissues for eQTL 
analyses were from patients who underwent lung surgery at three academic sites, Laval 
University, University of British Columbia (UBC), and University of Groningen. Whole-
genome gene expression profiling in the lung was performed on a custom Affymetrix array 
(GPL10379). Microarray pre-processing and quality controls were described previously. 
Genotyping was carried on the Illumina Human 1M-Duo BeadChip array. Genotypes and 
gene expression levels were available for 409, 287 and 342 patients at Laval, UBC, and 
Groningen, respectively. (ii) NCI RNAseq eQTL study: RNA was extracted from lung tissue 
samples within the Environment and Genetics in Lung cancer Etiology (EAGLE) study. 
RNAseq was carried out on 90 lung tissue sampled from an area distant from the tumor 
(defined here as “non-malignant lung tissue”) to minimize the potential for local cancer field 
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effects. Transcriptome sequencing of 90 non-tumor samples was performed on the Illumina 
HiSeq2000/2500 platform with 100-bp paired-end reads. Genotyping was undertaken using 
Illumina bead arrays as described previously. (iii) GTEx: eQTL summary statistics based on 
RNAseq analysis were obtained for eQTL summary statistics from the GTEx data portal 
http://www.gtexportal.org/home/35. This data included 278 individuals with data from lung 
tissue. Details of these three eQTL studies are included in the Supplementary Note.
The Microarray eQTL study was used as a discovery cohort. Probe sets located within 1 Mb 
up and downstream of lung cancer SNPs were considered for cis-eQTL analyses. We have 
also explored a 5 Mb interval for lung cancer-associated SNPs not acting as lung eQTL 
within the 1 Mb window. The top eQTL association for that sentinel variant (or if contained 
multiple eQTL’s with P-value<0.0005 each was considered), this particular eQTL was then 
chosen and assessed specifically in the independent NCI and GTEx RNAseq eQTL datasets. 
Statistical significance was defined the eQTL surpassed a locus specific Bonferroni 
correlation in the discovery cohort (P-value=0.05/number of probes at that locus) and 
subsequently there was evidence for replication of the eQTL effect with that variant and 
gene within the validation cohorts (NCI/GTEx RNAseq).
Lung cancer susceptibility variants in other phenotypes
We assessed associations between sentinel genetic variant associated with lung cancer and 
other phenotypes, including smoking behavior Fagerstrӧm Test for Nicotine Dependence, 
lung function and telomere length. Additional details of these analyses for other phenotypes 
are described in Supplementary Note. Briefly:
Smoking behaviors—The effects of lung cancer sentinel variants and smoking behavior 
were assessed based on the meta-analysis across 3 studies: ever-smoking controls with 
intensity information from the Oncoarray studies (N=8,120), deCODE (N=40,882) and UK 
Biobank (N=42,044). The association with nicotine dependence was evaluated based on 
Fagerstrӧm Test for Nicotine Dependence (FTND) data collected in 4 studies (n=17,074): 
deCODE Genetics, Environment and Genetics in Lung Cancer Etiology (EAGLE), 
Collaborative Genetic Study of Nicotine Dependence (COGEND), and Study of Addiction: 
Genetics and Environment (SAGE) and among current smokers in one other study [Chronic 
Obstructive Pulmonary Disease Gene (COPDGene). The study-specific SNP association 
results were combined using fixed effects, inverse variance-weighted meta-analysis with 
genomic control applied. Specifically, for the 8p21 variant rs11780471, we additionally 
considered other aspects of smoking behavior data from UKBiobank, deCODE and 
OncoArray controls. We additionally included summary statistics for the rs11780471 
variants from the TAG consortium (described in detail in the Supplementary Note).
Lung function—The lung function in silico look up was conducted in SpiroMeta 
consortium, which included 38,199 European ancestry individuals. The genome-wide 
associations between genetic variants and forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) and FEV1/FVC with 1000 Genomes Project (phase 1)-imputed 
genotypes in the GWAS with 38,199 individuals36.
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Telomere Length (TL)—Sentinel genetic variants associated with telomere length were 
those described by Codd et al22. Telomere lengths in 6,766 individuals from the UK Studies 
of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) study controls using a 
real-time PCR methodology and genotyping as described in Pooley et al., 201337.
Genetic heritability and correlations
Genome-wide SNP heritability and correlation estimates were obtained using association 
summary statistics and linkage disequilibrium (LD) information through LD Score (LDSC) 
regression analyses38,39. These analyses were restricted to HapMap3 SNPs with minor allele 
frequency above 5% in European populations of 1000 Genomes. Association summary 
statistics used for these analyses were based on lung cancer histological/smoking types (lung 
cancer overall, adenocarcinoma, squamous cell, small cell, ever smokers and never smokers) 
and smoking behavior parameters (cigarettes per day (CPD), smoking status (ever vs never 
smokers), and smoking cessation (current vs former smokers) from TRICL-ILCCO 
OncoArray consortium and Tobacco And Genetics consortium (https://
www.med.unc.edu/pgc/downloads)40.
Estimating the percentage of familial relative risks explained
The familial relative risk to a first degree relative accounted for by an individual variant 
(denoted as λi) is estimated based on relative risk per allele and allele frequency for that 
variant, using the method described in Hemminki et al41, and Bahcall42, under the 
assumption of log-additive effect. Assuming the effects of all susceptibility variants 
combined multiplicatively and not in linkage disequilibrium, the combined effect (λT) can 
then be expressed as the product of all λi. The proportion of the familial relative risk 
attributable to the totality of the susceptibility variants can then be computed as log(λT)/
log(λP). For lung cancer, the λP is approximately 2.0 based on the family cancer 
databases26,27. The percentage reported is based on the 18 sentinel variants reported in Table 
2. The multiple independent alleles in the same locus are not accounted for in this 
estimation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plots of lung cancer risk overall and by histological subtypes
(a) lung cancer risk overall, 29,266 cases and 56,450 controls (b) adenocarcinoma, 11,273 
cases and 55,483 controls (c) squamous cell carcinoma 7,426 cases and 55,627 controls. 
Each locus is annotated by their cytoband locations. The X‐axis represents chromosomal 
locations and the Y‐axis represents −log10(P‐value). Black denotes the previously known 
loci and Red denotes the new loci identified in this analysis
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Figure 2. Scatter plots comparing variants across the 6q27, 15q21.1, 8p12 and 11q23.3 
susceptibility loci and (Y-axis) their associated with lung cancer (or lung adenocarcinoma, as 
relevant) and (X-axis) the lung cis–eQTL (GTEx)
Each variant (dot) is colored relative the degree of linkage disequilibrium (r2) with sentinel 
lung cancer variant (marked) at that locus. Indented table, association between sentinel 
variant and lung cancer (or histological subtype) as well as the eQTL evidence in lung 
epithelium for the microarray (Laval, UBC, Groningen) and RNAseq (NCI and GTEx) 
cohorts. At 6q27, 15q21.1 and 8p12, the variants associated with lung cancer also tend to be 
those that that are lung cis-eQTL’s for RNASET2, SECISBP2L and NRG1, respectively. At 
11q23.3, while the sentinel variant (rs1056562) is a lung cis-eQTL for AMICA1, additional 
variants are AMICA1 lung cis-eQTL’s, but not associated with lung adenocarcinoma and 
vice versa suggesting an alternate candidate gene may be responsible for this association or a 
pleiotropic effect at this locus.
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Figure 3. eQTL and smoking behavior analysis of the 8p21 lung cancer susceptibility locus. 
Upper panel
Scatter plots of variants across the 8p21 locus and their associated with lung cancer (Y-axis) 
and CHRNA2 eQTL (X-axis) in lung epithelial tissues (panel a) and CHRNA2 eQTL in 
brain cerebellum tissues (panel b). Panel C. eQTL association between rs11780471 across 
tissues from different parts of the brain from GTEx and Braineac consortia noting CHRNA2 
cis- eQTL effect appears restricted to the brain cerebellum. Panel D. Association between 
rs11780471 and smoking phenotypes, noting evidence for association between smoking 
status (ever vs never) and age of initiation, with lung cancer risk allele carriers (G) more 
likely to be ever smokers and take up smoking earlier. Fagerström Test for Nicotine 
Dependence (FTND) index, error bars indicate the 95% confidence intervals.
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Table 1
Demographic characteristics of the participating studies after quality control filters
Lung cancer patients Controls
number (%) number (%)
OncoArray studies- passed QC 14803 (51) 12262 (22)
Published GWAS studiesa 14463 (49) 44188 (78)
Total 29266 56450
Age
 <=50   3112 (12)   6032 (12)
 >50 23025 (88) 44075 (88)
Sex
 Male 18208 (62) 27178 (53)
 Female 11059 (38) 24069 (47)
Smoking status
 Never   2355   (9)   7504 (31)
 Ever 23223 (91) 16964 (69)
 Former   9037 (35)   8554 (35)
 Current 13356 (52)   7477 (31)
Histology c
 Adenocarcinoma 11273 (39)
    55483 b
 Squamous cell carcinoma   7426 (25)
    55627 b
 Small cell carcinoma   2664   (9)
    21444 b
a
Previous GWAS studies include IARC, MDACC, SLRI, ICR, Harvard, ATBC, CPSII, German and deCODE studies.
bNumber of non-cancer individuals included in the corresponding histology-specific analysis.
c
The remaining 27% includes other histological subsets, such as large cell carcinoma, non-small cell lung cancer, NOS, mixed histology, and 
unknown.
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